Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?
Nexalin stock surged 69.47% due to positive clinical data release. Gen-2 Nexalin DIFS technology shows improved cognitive performance in Alzheimer's patients. Significant enhancements in functional connectivity and cognitive test scores were reported. No adverse events reported, affirming treatment safety and tolerability. Global strategy aims for FDA approval to expand treatment indications.
View signal analysis